文献速递儿童消化与营养儿童感染

静脉泮托拉唑在1至<2岁儿科患者中的安全性:美国真实世界回顾性队列研究

Safety of intravenous pantoprazole sodium in paediatric patients aged 1 year to <2 years: a real-world retrospective cohort study in the USA
RSS 订阅 · BMJ Paediatrics Open

本研究利用美国Optum纵向电子健康记录数据库(2007-2020年),纳入981例接受至少1剂静脉泮托拉唑的1至<2岁儿科患者,排除早产和出生体重<2.36 kg者。结果显示总体队列中呕吐、腹泻、腹胀、低钾血症和低钠血症发生率最高,且接受≥4天治疗的患者上述事件及血小板减少发生率高于<4天者。结论认为真实世界发生率与泮托拉唑已知安全性特征一致。

要点

  • 总体队列呕吐发生率最高(711.8/1000人年),其次为腹泻(412.4)和腹胀(234.9)。
  • 接受≥4天静脉泮托拉唑治疗者呕吐、腹泻、低钾血症、腹胀、低钠血症和血小板减少发生率高于<4天者。
  • 亚组2(GORD无EO)与亚组3(无GORD无EO)之间上述结局发生率相当。

核心结论

  • 真实世界中静脉泮托拉唑在1至<2岁儿科患者中的目标结局发生率与已知安全性特征一致。

研究设计与样本

  • 真实世界、非干预性、回顾性队列研究,使用Optum纵向电子健康记录数据库(2007年1月1日至2020年12月31日)。
  • 纳入981例接受至少1剂静脉泮托拉唑的1至<2岁患者,排除早产及出生体重<2.36 kg者。
  • 按GORD和EO诊断分为三个亚组:亚组1(GORD和EO)、亚组2(GORD无EO)、亚组3(两者均无)。

主要发现

  • 981例中亚组1无患者,亚组2有462例(47.1%),亚组3有519例(52.9%)。
  • 总体队列发生率最高的结局为呕吐(711.8/1000人年)、腹泻(412.4)、腹胀(234.9)、低钾血症(195.4)和低钠血症(182.5)。
  • 亚组2与亚组3之间上述结局发生率相当。
  • 接受≥4天治疗者呕吐、腹泻、低钾血症、腹胀、低钠血症和血小板减少发生率高于<4天者。

关键数值与推荐

  • 结局发生率以每1000人年报告。
  • 按静脉泮托拉唑治疗时长分层:<4天 vs ≥4天。

临床怎么用

  • 可为排除早产和低出生体重儿的1至<2岁儿科患者使用静脉泮托拉唑提供安全性参考。
  • 治疗≥4天时需关注呕吐、腹泻、低钾血症、腹胀、低钠血症和血小板减少的发生风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective To estimate the incidence rates (IRs) of outcomes of interest in paediatric patients (aged 1 to <2 years) treated with intravenous pantoprazole. Methods This real-world, non-interventional, retrospective study was conducted using Optum’s longitudinal electronic health records database between 1 January 2007 and 31 December 2020. Eligible patients receiving ≥1 dose of intravenous pantoprazole were included. Premature patients and those with birth weight <2.36 kg were excluded. Patients were divided into three subgroups based on diagnosis of gastro-oesophageal reflux disease (GORD) and erosive oesophagitis (EO): subgroup 1 (GORD and EO), subgroup 2 (GORD and no EO) and subgroup 3 (absence of both GORD and EO). The IRs (per 1000 person-years) of outcomes of interest were estimated in the overall and subgroups and stratified by duration of intravenous pantoprazole treatment (<4 days vs ≥4 days). Results Of 981 patients, none were identified in subgroup 1, while subgroup 2 and subgroup 3 comprised 462 (47.1%) and 519 (52.9%) patients, respectively. The highest IRs in the overall cohort were observed for vomiting (711.8), diarrhoea (412.4), abdominal distension (234.9), hypokalaemia (195.4) and hyponatraemia (182.5) with comparable IRs between subgroups 2 and 3. The IRs were higher for vomiting, diarrhoea, hypokalaemia, abdominal distension, hyponatraemia and thrombocytopenia in patients receiving ≥4 days of pantoprazole treatment versus <4 days. Conclusion The real-world incidence of the outcomes of interest is consistent with the established safety profile of pantoprazole and may provide key insights for use of intravenous pantoprazole in paediatric patients excluding those born preterm or with low birth weight.

来源:BMJ Paediatrics Open,查看原文。版权归原作者所有。

引用

  1. BMJ Paediatrics Open:Safety of intravenous pantoprazole sodium in paediatric patients aged 1 year to <2 years: a real-world retrospective cohort study in the USA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。